Axitinib Licensed by Pfizer

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Axitinib Chemical Structure

Axitinib Chemical Structure
Molecular Weight: 386.47

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Axitinib Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Targets VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)

 View  More

IC50 0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM
In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellMkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPjSFdqUUN3ME2wMlAxODB3MUOg{txOMV3TRW5ITVJ?
NCI-H1703Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnoTWM2OD1yLkCwNFkxOiEQvF2=MYnTRW5ITVJ?
KASUMI-1M17G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrLZoJKSzVyPUCuNFA3QDJizszNNYjSNVBzW0GQR1XS
CGTH-W-1M1K4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3OyR2lEPTB;MD6wNFczOiEQvF2=M{LFSnNCVkeHUh?=
A204M4nDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfrTWM2OD1yLkCwPVkzKM7:TR?=NWDIboxmW0GQR1XS
HOP-62NXv2SHUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlO0TWM2OD1yLkGwPFM3KM7:TR?=NWnmR3dpW0GQR1XS
H-EMC-SSNIjZbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILoWZhKSzVyPUCuNVExODVizszNM3HuZXNCVkeHUh?=
KU812M3TFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvITWM2OD1yLkG2OVc4KM7:TR?=MYTTRW5ITVJ?
EM-2MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rze2lEPTB;MD6xOlgyPiEQvF2=MmW0V2FPT0WU
LAMA-84NU\FdFJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPZUo1KSzVyPUCuNVc3PjVizszNM2PUb3NCVkeHUh?=
JARNXzTfXdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17hVmlEPTB;MD6yN|k5QSEQvF2=NFTyWHpUSU6JRWK=
G-361NH74[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PKR2lEPTB;MD6zNlMzPSEQvF2=M2rabnNCVkeHUh?=
KG-1NH7rPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jOPWlEPTB;MD6zO|Y1OiEQvF2=NHTRXJBUSU6JRWK=
BV-173MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETHWVZKSzVyPUCuN|k{OiEQvF2=M1PmXXNCVkeHUh?=
K5MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTBwNEKxNlch|ryPMYHTRW5ITVJ?
MEG-01NIXISVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXe2Rlk1UUN3ME2wMlQzOzZzIN88US=>MYDTRW5ITVJ?
MFM-223M2LMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLQcpdKSzVyPUCuOFQ4PzZizszNM4jJeHNCVkeHUh?=
BE-13NY\h[osxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXi[GJ4UUN3ME2wMlUyODB6IN88US=>MXPTRW5ITVJ?
NEC8NFT6dXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwN{KxNVMh|ryPNGLZfIlUSU6JRWK=
SW756NXu0XotoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\RVWlEPTB;MD65PVg1PiEQvF2=MUTTRW5ITVJ?
A2780NXHhOG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTFwMEGxOFYh|ryPNHPYe2RUSU6JRWK=
NB14MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Hp[mlEPTB;MT6wNVgxOSEQvF2=MXPTRW5ITVJ?
H4Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TaSmlEPTB;MT6wOlQzOiEQvF2=NWToNYI2W0GQR1XS
SK-OV-3MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlW4TWM2OD1zLkC2OlM{KM7:TR?=MkT4V2FPT0WU
AN3-CAMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTFwMEizPFkh|ryPNIfr[5NUSU6JRWK=
A427NHz1NnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mni1TWM2OD1zLkGwN|gyKM7:TR?=MoC2V2FPT0WU
ES7NYrCVmxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnH1TWM2OD1zLkGxN|M1KM7:TR?=M1rwbnNCVkeHUh?=
AGSNETUdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTFwMUGzPVUh|ryPNVLRPI5EW0GQR1XS
G-402NFjScJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHtPIZKSzVyPUGuNVQ3QTRizszNMVzTRW5ITVJ?
ES5NUXpUYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTFwMUeyOFgh|ryPM2XoO3NCVkeHUh?=
DELMoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLHR|VzUUN3ME2xMlI2PDV5IN88US=>Mm\TV2FPT0WU
NB10M4TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLITWM2OD1zLkOyOVU4KM7:TR?=NVXwRW5SW0GQR1XS
NCI-H1581M{nGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTFwM{mwOFIh|ryPNY\mZXI2W0GQR1XS
D-566MGNX[y[Y1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGGyTZdKSzVyPUGuOFA3QDNizszNMljjV2FPT0WU
LXF-289M{DX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nHdmlEPTB;MT60N|k6PiEQvF2=NEXDXYpUSU6JRWK=
BT-549M2HBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTFwNU[5NFkh|ryPM3PISHNCVkeHUh?=
NKM-1NXu1RploT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFwNkC1OVYh|ryPNUm5dIdHW0GQR1XS
SW780NEHJTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTFwNkWxOVgh|ryPNGDCPXdUSU6JRWK=
NCI-H292MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVr0[2JoUUN3ME2xMlY3Ozh|IN88US=>NHHXcIpUSU6JRWK=
HMV-IINXHzU2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7I[ohKSzVyPUGuO|A1QDhizszNNGn5PFBUSU6JRWK=
ALL-PONWXQ[mw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLre2c4UUN3ME2xMlgxODF3IN88US=>M3LJZXNCVkeHUh?=
UACC-257NUCzeFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTFwOEKxOlMh|ryPNVK5Z2VEW0GQR1XS
PA-1NVnGOlB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjV[ndCUUN3ME2xMlgzPzJ3IN88US=>M3TwcXNCVkeHUh?=
HD-MY-ZNGLvdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXMdlhKSzVyPUGuPFYzQDFizszNNE\5ZXFUSU6JRWK=
HSC-4MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTFwOUO4N|kh|ryPNUDteFVXW0GQR1XS
GCTM3HVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTvdVN6UUN3ME2yMlAxQTF4IN88US=>MnnvV2FPT0WU
RT-112M2LDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\uTWM2OD1{LkGzOFI1KM7:TR?=MnrYV2FPT0WU
A172NUDjRoh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHXT3MxUUN3ME2yMlE{PjB4IN88US=>Ml;rV2FPT0WU
HCE-TNXLN[XV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJwMkC1PVgh|ryPNYm2Zmd6W0GQR1XS
YH-13MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTJwMkG2O|Eh|ryPMYjTRW5ITVJ?
DK-MGNHzX[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHW2O3pKSzVyPUKuNlM5OzRizszNMWjTRW5ITVJ?
ACNNUjNNI1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJwMkO4O|Uh|ryPM1y5bHNCVkeHUh?=
VA-ES-BJNVrmPYZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjDTGJ{UUN3ME2yMlI1QTV5IN88US=>M3X0TnNCVkeHUh?=
L-363M1zjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4q1fGlEPTB;Mj6yPFA3OSEQvF2=NXrL[I9KW0GQR1XS
HuH-7NGrzTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzrbWtZUUN3ME2yMlQzOTZ3IN88US=>NV\BfXJxW0GQR1XS
A4-FukMkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTCTWM2OD1{LkS3NVY5KM7:TR?=NWOzcXRGW0GQR1XS
T-24NUT1WYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTaWZNnUUN3ME2yMlQ5ODN5IN88US=>MVPTRW5ITVJ?
GOTOMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jQUWlEPTB;Mj61N|AyOyEQvF2=M4q2XXNCVkeHUh?=
MV-4-11M1nPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjXXoxKSzVyPUKuOVkyPjlizszNMlruV2FPT0WU
DMS-114NXzZfFlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\hR2lEPTB;Mj62OlM1PSEQvF2=MVnTRW5ITVJ?
MHH-NB-11MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DPe2lEPTB;Mj63NFI6QSEQvF2=Mn[4V2FPT0WU
CHP-212NFfWWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTJwOEKwPVEh|ryPMW\TRW5ITVJ?
DMS-273MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnJUIJKSzVyPUKuPVAzODdizszNMUnTRW5ITVJ?
SF295MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fqb2lEPTB;Mz6wNlU6PyEQvF2=MmjWV2FPT0WU
NCI-H1563NYq0foR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUG1dHg3UUN3ME2zMlE2ODB3IN88US=>NYHHTWZRW0GQR1XS
NCI-H446NGq0dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTNwMkK4NFUh|ryPNFPRSnpUSU6JRWK=
HCC1806NUXtPWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfGN5lKSzVyPUOuNlc3PTdizszNMWTTRW5ITVJ?
SF126MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7uTWM2OD1|LkOwNFE4KM7:TR?=NXHNWlFxW0GQR1XS
SW982MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjNbFN4UUN3ME2zMlM{QDd3IN88US=>Mo\kV2FPT0WU
ES8NFf6RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7XTWM2OD1|LkO0PVk6KM7:TR?=NH:2V3ZUSU6JRWK=
SCC-4NGjVdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mor1TWM2OD1|LkWwN|k3KM7:TR?=NHXLVllUSU6JRWK=
RPMI-8226M2fFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTNwNkK2NVYh|ryPMUnTRW5ITVJ?
EW-11MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjiVGhKSzVyPUOuOlMxOjJizszNNETYbmlUSU6JRWK=
COR-L105M2T5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTNwNkOzN|Qh|ryPMmr0V2FPT0WU
ES1M2\vcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXDTWM2OD1|LkizNFk1KM7:TR?=Ml7VV2FPT0WU
KMOE-2MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrWeoRTUUN3ME2zMlkyQDB6IN88US=>M3zifHNCVkeHUh?=
ABC-1NXvvTY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj1SohKSzVyPUOuPVM6OTFizszNMmD0V2FPT0WU
NCI-H526M3TZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2j4W2lEPTB;Mz65PVEzPiEQvF2=M1PXNnNCVkeHUh?=
HCC1395NVnK[Jp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\4WmdKSzVyPUOuPVk1QDRizszNMoq3V2FPT0WU
DU-145M2PkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTRwMUK4NlUh|ryPMYXTRW5ITVJ?
JEG-3MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXHblJKSzVyPUSuNVU6OTZizszNNXmxOms4W0GQR1XS
HCC1187NXL2Z2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTRwMkG1PVch|ryPNYLlUlhuW0GQR1XS
LC-2-adMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfVTWM2OD12LkKyNVc4KM7:TR?=M17FWHNCVkeHUh?=
ONS-76MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn:2TWM2OD12LkK0NVkzKM7:TR?=M4qwb3NCVkeHUh?=
CAL-27MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV30eGZFUUN3ME20MlI1OzR2IN88US=>M4\6R3NCVkeHUh?=
8-MG-BAM4T2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPFTWM2OD12LkK2OlU5KM7:TR?=MnnpV2FPT0WU
HGC-27NYfUS2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvYbHFKSzVyPUSuNlk3PiEQvF2=NYPn[ndUW0GQR1XS
Hs-578-TNILtWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XJdWlEPTB;ND6zNVQ3QCEQvF2=NUT4WIh7W0GQR1XS
EW-1NWG4NXNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7OTWM2OD12LkWzNFE1KM7:TR?=MV\TRW5ITVJ?
SW1573MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17HO2lEPTB;ND61OVE3OyEQvF2=M1;4XnNCVkeHUh?=
SNU-423MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIThTIpKSzVyPUSuOlA4QSEQvF2=MX7TRW5ITVJ?
HOSMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlT2TWM2OD12Lk[5O|ch|ryPMnHtV2FPT0WU
LB1047-RCCMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEewcoNKSzVyPUSuPFE1OThizszNMWnTRW5ITVJ?
ChaGo-K-1NYjMSnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTRwOEmwOFgh|ryPM4ftXHNCVkeHUh?=
A3-KAWNFXWc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFuwXoFKSzVyPUSuPVc{PTJizszNM4HrTnNCVkeHUh?=
CAS-1NXr2XpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHMTWM2OD12Lkm5PVA5KM7:TR?=Mn25V2FPT0WU
NBsusSRMnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIn2O|VKSzVyPUWuNFM2OTRizszNNWXwSG1CW0GQR1XS
KM12NW\T[41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4n1V2lEPTB;NT6yPVgzPyEQvF2=MnnsV2FPT0WU
NCI-H1155NXnLR2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVy1OlhkUUN3ME21MlM5OTh3IN88US=>MVXTRW5ITVJ?
EFM-19M3TJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1KyXmlEPTB;NT60NVc{PyEQvF2=MV7TRW5ITVJ?
D-392MGM1PRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTVwNUe4OFkh|ryPM2PjXnNCVkeHUh?=
JVM-3MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEP2ZnRKSzVyPUWuO|I{OjVizszNM3HyVXNCVkeHUh?=
EW-16NX\EOGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XqRmlEPTB;NT63OVU5OyEQvF2=MlPjV2FPT0WU
KARPAS-45M1HsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTVwOESzNlUh|ryPM3fyN3NCVkeHUh?=
NCI-H28M4O4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PEV2lEPTB;NT64O|kyQCEQvF2=MYrTRW5ITVJ?
COLO-829M{O4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTVwOUG1NFQh|ryPMUHTRW5ITVJ?
KM-H2MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj4SohKSzVyPUWuPVI{QTVizszNMnTBV2FPT0WU
NCI-H82MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3lTWM2OD13LkmyO|cyKM7:TR?=NVnWZZNDW0GQR1XS
OAW-42M4Lo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjXNXZkUUN3ME21Mlk5QDJzIN88US=>M{LX[3NCVkeHUh?=
A704M2[xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;ZencxUUN3ME22MlExPTd2IN88US=>NXjGT203W0GQR1XS
NCI-H1048M4HtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkmyTWM2OD14LkGwOVk6KM7:TR?=M1zGcXNCVkeHUh?=
LOXIMVINFXSVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkT5TWM2OD14LkGxNlQ5KM7:TR?=MUPTRW5ITVJ?
MKN45NX\wVGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjjU|NKSzVyPU[uNlYxOTZizszNNFnY[|NUSU6JRWK=
D-502MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjiTWM2OD14LkK4PFU4KM7:TR?=NIn3PYRUSU6JRWK=
HUTU-80NWXOPIxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTZwNEG2PFgh|ryPNHfjeHdUSU6JRWK=
S-117MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLOTWM2OD14LkWwNlY4KM7:TR?=MVrTRW5ITVJ?
HCC1569MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTZwNUO3N|ch|ryPNYH3TpZnW0GQR1XS
J-RT3-T3-5MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInaS4VKSzVyPU[uOVQ2PzJizszNMojqV2FPT0WU
OC-314MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTZwOUGxOVkh|ryPM2fQWnNCVkeHUh?=
SNU-449MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TGVmlEPTB;Nz6wNVA4OiEQvF2=MVvTRW5ITVJ?
NCI-H720NH\XU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz2XVdxUUN3ME23MlE6OzR3IN88US=>Mn3TV2FPT0WU
KP-N-YSMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jLUWlEPTB;Nz6yNFczKM7:TR?=MnvUV2FPT0WU
IGROV-1NWjWe3A3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HzZ2lEPTB;Nz6zNlM5PiEQvF2=NF61V|hUSU6JRWK=
SK-PN-DWM2\3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HZTmlEPTB;Nz60PFE2KM7:TR?=NEDudXpUSU6JRWK=
HCC1419NF3COmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrCbJJLUUN3ME23MlU{KM7:TR?=MUfTRW5ITVJ?
HAL-01MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTdwNkC2OFQh|ryPMVHTRW5ITVJ?
HCC2998NGnoc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTdwNkC3OFMh|ryPNVTVV3dCW0GQR1XS
SK-N-FIM2HJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTdwNkOwN|Mh|ryPMkexV2FPT0WU
GI-ME-NMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTdwNkS5N|Qh|ryPMXTTRW5ITVJ?
SW1088M1fWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PFNWlEPTB;Nz62OVgzPiEQvF2=M{HqUXNCVkeHUh?=
IA-LMNH\mVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn4TZVEUUN3ME23MlY5PjF|IN88US=>MonUV2FPT0WU
SK-NEP-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHyTWM2OD15Lk[5OlEh|ryPNHvxdXNUSU6JRWK=
MDA-MB-415NFz3epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTdwOEmxPFYh|ryPNUfmSXk6W0GQR1XS
COLO-800M3nrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTdwOUS0PVIh|ryPMl;HV2FPT0WU
NCI-H2228NETQTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LxTWlEPTB;OD6xOVc5OyEQvF2=M33JTXNCVkeHUh?=
D-423MGMlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTHbZdKSzVyPUiuNlE4OiEQvF2=NWSwXJJ1W0GQR1XS
TE-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3[y[2lEPTB;OD60OFMyPiEQvF2=M1LQeXNCVkeHUh?=
NOS-1M2XlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDM[WxKSzVyPUiuOVE2OzRizszNMnXBV2FPT0WU
8505CNGnLfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjJcWt6UUN3ME24MlY1QDJ2IN88US=>NXTSd5E3W0GQR1XS
HEC-1NHvQfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfHZnd[UUN3ME24Mlc5PDN7IN88US=>M2jkOXNCVkeHUh?=
TE-11M{C3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRThwOUm1OVEh|ryPMmftV2FPT0WU
CTB-1NYruSlVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTlwMEG0N|Mh|ryPM{DaRnNCVkeHUh?=
TGBC11TKBNEnW[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PSR2lEPTB;OT6wNlI1OSEQvF2=NECzWmVUSU6JRWK=
NB17NIPWeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTlwMUi4O{DPxE1?M37P[HNCVkeHUh?=
BeckerMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTlwNEG5OFQh|ryPMni3V2FPT0WU
SN12CM2r3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPYdm5KSzVyPUmuOFUzOzRizszNNXn0VVVuW0GQR1XS
COLO-320-HSRNX7yUXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDYO5oyUUN3ME25MlYxOjN5IN88US=>NIn5fmpUSU6JRWK=
D-283MEDMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPESldKSzVyPUmuOlMxPzJizszNMmDiV2FPT0WU
D-263MGNWrXXo5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofTTWM2OD17LkizN|g1KM7:TR?=M3;HTXNCVkeHUh?=
MEL-JUSONFTzZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTlwOUCxNlch|ryPMkXGV2FPT0WU
T98GNXHHdHhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDsTWM2OD17LkmwNlA{KM7:TR?=MmHzV2FPT0WU
HLENXnqUItmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fmSmlEPTB;OT65NFkxQSEQvF2=NWnPNXlUW0GQR1XS
Ca9-22M4HHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFyLkC2OlUh|ryPM4DJVXNCVkeHUh?=
OS-RC-2MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvPTWM2OD1zMD6xNFQ2KM7:TR?=MmjLV2FPT0WU
T47DNISxcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUOzdYJsUUN3ME2xNE4yPTVizszNM2nITnNCVkeHUh?=
GI-1NFXvRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHrc2lKSzVyPUGwMlM2OzNizszNM{TqbnNCVkeHUh?=
NUGC-3NYTuUmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWP4Z4RzUUN3ME2xNE41PDB{IN88US=>MojHV2FPT0WU
MDA-MB-361M4fZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFyLkS0N|Ih|ryPNEeydJRUSU6JRWK=
SCC-15NI\2PWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml[xTWM2OD1zMD60O|E5KM7:TR?=NFf5Z3ZUSU6JRWK=
KS-1NHnjOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLq[3JEUUN3ME2xNE43OzBzIN88US=>MmPZV2FPT0WU
CAL-12TNYTLW5Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2f4bWlEPTB;MUCuOlM3OSEQvF2=NILjZ3hUSU6JRWK=
OVCAR-4NEHoeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\qcoRjUUN3ME2xNE44ODZ6IN88US=>M1\PWHNCVkeHUh?=
HuP-T4MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHqTWM2OD1zMT6wN|I5KM7:TR?=MX7TRW5ITVJ?
NCI-H358MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjGO3RCUUN3ME2xNU4zPjV5IN88US=>NFv3NFNUSU6JRWK=
HO-1-N-1M4XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDqTWM2OD1zMT6zN|k5KM7:TR?=MWjTRW5ITVJ?
NH-12MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFzLkWzO|gh|ryPM174VXNCVkeHUh?=
MOLT-4NEDGVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTFzLkW5PFUh|ryPM4PJPHNCVkeHUh?=
K-562M{PTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7nTWM2OD1zMT63NlQ5KM7:TR?=M1LsT3NCVkeHUh?=
ES6MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTzT5dMUUN3ME2xNU45PThzIN88US=>M2XkRXNCVkeHUh?=
RO82-W-1M3i4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTFzLkmwOlQh|ryPNX34SolIW0GQR1XS
Ramos-2G6-4C10NVOyb4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPMVpRKSzVyPUGxMlk{OiEQvF2=MXfTRW5ITVJ?
23132-87MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHueIVKSzVyPUGyMlA5OjFizszNNF;s[3lUSU6JRWK=
A549NG[4dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn[wTWM2OD1zMj6zNlg2KM7:TR?=NFXvXWRUSU6JRWK=
NCI-H23NGq4TGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojLTWM2OD1zMj61NFI3KM7:TR?=NYPiUHFDW0GQR1XS
H9MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\z[mlEPTB;MUKuOVU4PyEQvF2=MYnTRW5ITVJ?
LB771-HNCNHziO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13x[GlEPTB;MUKuO|Y2KM7:TR?=NXLad4VoW0GQR1XS
QIMR-WILNYfuXXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\1dmlEPTB;MUKuPFI2QCEQvF2=NG\SXoVUSU6JRWK=
HSC-3NGT2OVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXv6[YtVUUN3ME2xNk46Ojd4IN88US=>MYHTRW5ITVJ?
PFSK-1NVT3VoF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHkZYpKSzVyPUGyMlk2ODdizszNMYHTRW5ITVJ?
ETK-1NXvqUWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTF|LkC3O|kh|ryPNXrvSWF5W0GQR1XS
SW1710Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3ETWM2OD1zMz6zOlQyKM7:TR?=M4X5THNCVkeHUh?=
COLO-684NUL1T2MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jUN2lEPTB;MUOuOFU1OSEQvF2=MYPTRW5ITVJ?
RPMI-7951NU\4[JhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPqNpBKSzVyPUGzMlUyOzZizszNMoXVV2FPT0WU
A101DNVfQfGFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF[wO5JKSzVyPUGzMlU{PDlizszNNIfiVJFUSU6JRWK=
KE-37Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTF|LkW4PFch|ryPNGfZenZUSU6JRWK=
SiHaMo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2KyfWlEPTB;MUOuPFM1PiEQvF2=MUjTRW5ITVJ?
NCI-H226NUfnc2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jYOmlEPTB;MUOuPFgxQCEQvF2=NI\3eWZUSU6JRWK=
DBMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnyVIlsUUN3ME2xN{46QTJ6IN88US=>NIjhelBUSU6JRWK=
HT-1197MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF2LkC4NFkh|ryPNHu1WJdUSU6JRWK=
SBC-5M3H1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfITWM2OD1zND6xN|YzKM7:TR?=NVrnW4p[W0GQR1XS
VMRC-RCZNGPrR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2K1SWlEPTB;MUSuOVc4PCEQvF2=NGLqSHBUSU6JRWK=
697M{nVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\RfWtEUUN3ME2xOE43OjdizszNMYTTRW5ITVJ?
OMC-1MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDSTWM2OD1zND63PFg5KM7:TR?=M1znRnNCVkeHUh?=
SKG-IIIaMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX6yXVdRUUN3ME2xOE45ODBzIN88US=>MoG4V2FPT0WU
DOKMnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvlfm1KSzVyPUG0Mlk6OzNizszNNIf0WVBUSU6JRWK=
NCI-H2029MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF3LkO2NFIh|ryPNFzNeWNUSU6JRWK=
NCI-H2009NFniRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnzUGRKSzVyPUG1MlUxQTVizszNMnKyV2FPT0WU
LK-2NIDiXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;VTWM2OD1zNT62OFQ6KM7:TR?=Mon1V2FPT0WU
NCI-H661NEizco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXztVIk1UUN3ME2xOU46ODd3IN88US=>NWrhSXNzW0GQR1XS
GT3TKBNHfFXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTF4LkC2O|Yh|ryPM3GxcHNCVkeHUh?=
GP5dMnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWf2ZXc2UUN3ME2xOk4{PDJizszNMYDTRW5ITVJ?
SK-MEL-2NGHuOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHniUnlKSzVyPUG2MlQ1QDVizszNMYLTRW5ITVJ?
SK-UT-1Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3KwTWlEPTB;MU[uOVY2KM7:TR?=NVm3elFHW0GQR1XS
NB7NVL5U2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\Cd2lEPTB;MU[uOlk4OSEQvF2=Mn3HV2FPT0WU
NCI-H460NHfzUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zkfmlEPTB;MU[uO|MzPiEQvF2=MmrEV2FPT0WU
8305CNWqxdJJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDpVGJSUUN3ME2xOk44QDd5IN88US=>MUfTRW5ITVJ?
CaR-1M2[0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTF4LkixNVEh|ryPMVPTRW5ITVJ?
D-247MGNV\TZ3BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELJfJJKSzVyPUG2Mlg3OjVizszNMnvvV2FPT0WU
LoVoMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF4Lkm0PFgh|ryPMX;TRW5ITVJ?
NCI-H2405NFPJUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfUTWM2OD1zNz6xPVA5KM7:TR?=MnTHV2FPT0WU
AU565NFGxfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT1TWM2OD1zNz6yNlUh|ryPMoG0V2FPT0WU
OCI-AML2M2PrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HB[GlEPTB;MUeuOVMyPyEQvF2=MnXHV2FPT0WU
22RV1M{fYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTF5LkW4PFQh|ryPNXHMVmlnW0GQR1XS
HT-144MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELS[JVKSzVyPUG3MlY2QThizszNMnX2V2FPT0WU
HuO9M2rSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjYTWM2OD1zNz63NFMyKM7:TR?=NWDXT5RsW0GQR1XS
DaoyNXGxfmVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1SzV2lEPTB;MUeuO|E5PCEQvF2=M{\0WHNCVkeHUh?=
SJRH30M{XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXHXVNuUUN3ME2xO{45PDh7IN88US=>NIG4OoRUSU6JRWK=
CHL-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DHd2lEPTB;MUeuPVI1QSEQvF2=MVvTRW5ITVJ?
J82NYPx[IhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XLUGlEPTB;MUeuPVY{PSEQvF2=MV\TRW5ITVJ?
COR-L23NFrycZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPnTWM2OD1zOD6wNFEyKM7:TR?=NYXNcJluW0GQR1XS
SNU-C2BMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\WSINRUUN3ME2xPE4zOjd4IN88US=>MVXTRW5ITVJ?
NCI-H1770MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jlcGlEPTB;MUiuOFYyPSEQvF2=NHrBcIdUSU6JRWK=
MHH-PREB-1NHeycGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DnXmlEPTB;MUiuOVY6PyEQvF2=MlrZV2FPT0WU
ES3MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULVTFJqUUN3ME2xPE42QDh|IN88US=>NX;Kc|NqW0GQR1XS
MDA-MB-231M3HZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzpTJlVUUN3ME2xPE43PTB{IN88US=>MUfTRW5ITVJ?
MN-60M4P2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF7LkC1PVIh|ryPMVXTRW5ITVJ?
EPLC-272HMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTF7LkO3NFgh|ryPNF7wOIZUSU6JRWK=
SW948M3;tSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF7LkO5N|Qh|ryPMYXTRW5ITVJ?
MOLT-13M1T1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkmzTWM2OD1zOT60OVQ3KM7:TR?=NUfuTJlGW0GQR1XS
HL-60MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC2UnRKSzVyPUKwMlIyPDFizszNMlrWV2FPT0WU
CP50-MEL-BM3zSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moj3TWM2OD1{MD60O|Q5KM7:TR?=M4q3O3NCVkeHUh?=
NTERA-S-cl-D1NHy3VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHMUmxKSzVyPUKwMlQ6PzhizszNMnXNV2FPT0WU
KINGS-1M1W0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXuTWM2OD1{MD63PVY4KM7:TR?=M{C1XHNCVkeHUh?=
DOHH-2M3K0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\GUHUyUUN3ME2yNE46ODZizszNM1:1eXNCVkeHUh?=
BB65-RCCMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\mR2lEPTB;MkCuPVI5PSEQvF2=M2XkcnNCVkeHUh?=
NB12Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj2NXdKSzVyPUKxMlA{QTRizszNMkXaV2FPT0WU
KY821M130R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXYUGRPUUN3ME2yNU42QDJizszNNG\ZZpBUSU6JRWK=
PSN1NETQZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PLZWlEPTB;MkGuOlQ2OyEQvF2=M{LjR3NCVkeHUh?=
EGI-1M4m4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzyO5FKSzVyPUKxMlc1PTRizszNMYnTRW5ITVJ?
CTV-1NGLNVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHOTWM2OD1{Mj6zNFMyKM7:TR?=NVrMNm8yW0GQR1XS
TI-73MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jkOmlEPTB;MkKuN|Q6QCEQvF2=Ml7HV2FPT0WU
LCLC-103HMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLxdIpKSzVyPUKyMlQ4PTJizszNNGLKbnlUSU6JRWK=
D-542MGNHrmWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHQTWM2OD1{Mj61OVU5KM7:TR?=M33t[HNCVkeHUh?=
ATN-1NUXhR2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTJ{Lk[0N|kh|ryPNVnEdFJPW0GQR1XS
SK-MEL-1M3X2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTMd3J6UUN3ME2yNk45OzZ6IN88US=>MofjV2FPT0WU
HDLM-2M{XnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTO[WtKSzVyPUKzMlE1PzhizszNMn;WV2FPT0WU
UM-UC-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTJ|LkG5OFQh|ryPMVzTRW5ITVJ?
NCI-H1573NIPWO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXwTWM2OD1{Mz60OlgyKM7:TR?=NHfVcGNUSU6JRWK=
NCI-H520M1XtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jlVmlEPTB;MkOuOFk1QCEQvF2=M{nPfnNCVkeHUh?=
ESS-1NWfwOVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne5TWM2OD1{Mz64NFU6KM7:TR?=MneyV2FPT0WU
COR-L88M2X2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fKSWlEPTB;MkOuPVQ4PSEQvF2=MWrTRW5ITVJ?
TGBC24TKBNGPM[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJ2LkCzNVIh|ryPNWeweIk4W0GQR1XS
HCC1937NGT4R2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlu4TWM2OD1{ND6xJO69VQ>?MlLyV2FPT0WU
RS4-11M3niRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nmOGlEPTB;MkSuNVQzKM7:TR?=MWnTRW5ITVJ?
HCC38MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTJ2LkKzPVQh|ryPM3W1XnNCVkeHUh?=
RPMI-2650NVLqb4dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjWV2lKSzVyPUK0MlYyPjJizszNNEfORXdUSU6JRWK=
P12-ICHIKAWAMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTJ2Lk[yOVgh|ryPMX7TRW5ITVJ?
YAPCNHXwd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHaWpJKSzVyPUK0MlgzOTRizszNMUjTRW5ITVJ?
NB13MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXpbYtKSzVyPUK1MlI3OTFizszNMULTRW5ITVJ?
SK-N-ASMl7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPqNFVGUUN3ME2yOU45PTh2IN88US=>MVfTRW5ITVJ?
SK-N-DZNFr6T5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nCUGlEPTB;Mk[uNFQ6KM7:TR?=MnL4V2FPT0WU
LS-411NM2qz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGKyVlZKSzVyPUK2MlIxOzhizszNMXHTRW5ITVJ?
NCI-H810MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\0TWM2OD1{Nj6zNVEzKM7:TR?=MnjNV2FPT0WU
NCI-SNU-1M3Tj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fRUWlEPTB;Mk[uOVQ2PCEQvF2=NX\PSY5OW0GQR1XS
HHM{K3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\GTWM2OD1{Nj61OVI6KM7:TR?=MkTZV2FPT0WU
U-2-OSNYjEZ4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HJ[mlEPTB;Mk[uO|M5OiEQvF2=MX;TRW5ITVJ?
SF539MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nXU2lEPTB;Mk[uPFAyQCEQvF2=NVP1TGR4W0GQR1XS
NCI-H2052MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1Xa[mlEPTB;MkeuNFg3KM7:TR?=MlTSV2FPT0WU
A673NGfUcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTJ5LkKxNFIh|ryPM3SxUHNCVkeHUh?=
WM-115MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofWTWM2OD1{Nz63O|Y4KM7:TR?=MlPEV2FPT0WU
SW48NF7vZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{L5dmlEPTB;MkeuPFAxPSEQvF2=MlT5V2FPT0WU
NOMO-1MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfhTWM2OD1{Nz64OVMzKM7:TR?=MlzOV2FPT0WU
PC-3MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3wTWM2OD1{Nz64PVQyKM7:TR?=NFfqd2NUSU6JRWK=
UMC-11M1e2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\yWHpKSzVyPUK3Mlk{PDNizszNM37hZnNCVkeHUh?=
U-118-MGM1jL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjsVmFRUUN3ME2yPE4xOTJ|IN88US=>M4nXXnNCVkeHUh?=
NCI-H2452MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HoVWlEPTB;MkiuNFgzOiEQvF2=MYXTRW5ITVJ?
CAMA-1Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jJcmlEPTB;MkiuPFU3PCEQvF2=NX7vbIxOW0GQR1XS
MC-IXCM{DVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vPUWlEPTB;MkmuNlM3PiEQvF2=M{\IVnNCVkeHUh?=
ES4NU\rPJZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrBR2JKSzVyPUK5MlMyPzJizszNNYTTdlFvW0GQR1XS
BHT-101NEHyemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLjcXV2UUN3ME2yPU4{OjFizszNNGToVnZUSU6JRWK=
KP-4MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3n5PWlEPTB;MkmuOVE3KM7:TR?=NYjMTo1NW0GQR1XS
CAL-54M1WxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rRXmlEPTB;MkmuOVQ1PSEQvF2=MnuxV2FPT0WU
5637MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17TPGlEPTB;MkmuOlQzOSEQvF2=M{PZcnNCVkeHUh?=
MOLT-16M33lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX25ZXRJUUN3ME2yPU44OjZ7IN88US=>NFvxeWVUSU6JRWK=
Ca-SkiMn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mln5TWM2OD1{OT65OFYh|ryPNXL0coNzW0GQR1XS
AsPC-1NYrRXml5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLyTWM2OD1|MD6wNlEzKM7:TR?=MVHTRW5ITVJ?
MSTO-211HNHXTO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrPTWM2OD1|MD6xOUDPxE1?MoTrV2FPT0WU
L-428M17LV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DsSWlEPTB;M{CuOFA2KM7:TR?=NV\lc|duW0GQR1XS
SW1463NF74e|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zvbWlEPTB;M{CuOVM5OyEQvF2=NV;JNI5tW0GQR1XS
NCI-H1648MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XQRWlEPTB;M{CuOVU4PCEQvF2=MY\TRW5ITVJ?
CAKI-1MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PkSWlEPTB;M{CuO|cxOiEQvF2=MUfTRW5ITVJ?
YKG-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDiUpNKSzVyPUOxMlAzPjNizszNMmnDV2FPT0WU
A2058MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTOTWM2OD1|MT6xNVY1KM7:TR?=MYfTRW5ITVJ?
A375NXfKbohtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIridmtKSzVyPUOxMlE3QTZizszNNHTzOpFUSU6JRWK=
SNB75MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLzPXpzUUN3ME2zNU4zPDN3IN88US=>M1Kz[nNCVkeHUh?=
SK-HEP-1M4e5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTMcGdtUUN3ME2zNU41OjdzIN88US=>M3ra[nNCVkeHUh?=
ME-180M4LiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml32TWM2OD1|MT62OVQzKM7:TR?=M2nEV3NCVkeHUh?=
NCI-H209NWfy[W1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknOTWM2OD1|MT64NlQ4KM7:TR?=MoO0V2FPT0WU
HC-1NYHoUJBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXftfnlLUUN3ME2zNk4yPDR4IN88US=>MlHtV2FPT0WU
LB373-MEL-DMlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWiweItpUUN3ME2zNk4yQTdzIN88US=>MUPTRW5ITVJ?
SNU-387MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDY[YlKSzVyPUOyMlMyQTFizszNNUT5TGNvW0GQR1XS
C32MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PQUmlEPTB;M{KuN|M2OyEQvF2=NVPqOWRVW0GQR1XS
EW-13MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XLZ2lEPTB;M{KuPVQxQCEQvF2=Moe4V2FPT0WU
BFTC-905NFSwT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLYVJNKSzVyPUOzMlUyOzZizszNNHO5[3FUSU6JRWK=
NCI-H1299Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTN|LkW2NlEh|ryPMY\TRW5ITVJ?
LU-135M33OUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\ZTWM2OD1|Mz64NFEh|ryPM2DGXnNCVkeHUh?=
NCI-H2122MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrCfVdKSzVyPUOzMlk6PjZizszNNIXpXIdUSU6JRWK=
SK-LMS-1NH\TNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzCeGJpUUN3ME2zOE41OTB5IN88US=>MU\TRW5ITVJ?
LNCaP-Clone-FGCNHfHcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTN2Lki1NVUh|ryPNGHzUHpUSU6JRWK=
NCI-H1092Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjUPFNIUUN3ME2zOU4zPzR5IN88US=>MofnV2FPT0WU
MS-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\UbnFKSzVyPUO1MlMxOzhizszNNHXidY9USU6JRWK=
KYSE-510MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\WZXd7UUN3ME2zOU42ODR{IN88US=>M3\PZnNCVkeHUh?=
NCI-H1793Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvPTWM2OD1|NT62OVQ2KM7:TR?=MlPUV2FPT0WU
MIA-PaCa-2NVu0TFlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlm0TWM2OD1|Nj6wOFk3KM7:TR?=NFTQNIhUSU6JRWK=
EW-22MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nURmlEPTB;M{[uOFA4OiEQvF2=MmfPV2FPT0WU
IGR-1NVPXR5VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHlTWM2OD1|Nj64NVg1KM7:TR?=NHHiWJVUSU6JRWK=
HT-1080M17SN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rYb2lEPTB;M{euNVI2KM7:TR?=MYjTRW5ITVJ?
M14NXTse2lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTN5LkG2OFIh|ryPMlPFV2FPT0WU
786-0MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUC4PIN2UUN3ME2zO{4zPzl2IN88US=>MYLTRW5ITVJ?
MZ2-MELMmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XPfmlEPTB;M{euOFUxOSEQvF2=NUPodlhmW0GQR1XS
NCI-H510AMn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4iwT2lEPTB;M{euPVQyOiEQvF2=MX3TRW5ITVJ?
LAN-6M2XZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUSyc5ZbUUN3ME2zO{46PTh{IN88US=>NH7nUolUSU6JRWK=
SW620MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnBfIdKSzVyPUO4MlQ6PzRizszNMVPTRW5ITVJ?
LB2241-RCCMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTN7LkiyNFUh|ryPNX3JWoFGW0GQR1XS
Detroit562NILHUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\rc2lEPTB;NECuNVI3QCEQvF2=MknHV2FPT0WU
HNNGH2eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGS0[oNKSzVyPUSwMlE4QDJizszNNUTMT5NzW0GQR1XS
HCT-15MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rsN2lEPTB;NECuOVkxPyEQvF2=NIi1e5FUSU6JRWK=
C2BBe1MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3vTWM2OD12MD65NVU4KM7:TR?=NVjFW|JKW0GQR1XS
A498NWDv[mZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4T5dmlEPTB;NEGuN|AyPSEQvF2=NHnVdZdUSU6JRWK=
SK-MEL-24M2\FR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{G0UmlEPTB;NEGuOFczPSEQvF2=MYTTRW5ITVJ?
OVCAR-5NVr4cGd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPKTWM2OD12MT63O|Y4KM7:TR?=NFW0[I1USU6JRWK=
NCI-H1792NYnybXY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mme4TWM2OD12MT65PFIyKM7:TR?=NWLGXZZHW0GQR1XS
KOSC-2MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTR{LkK2PVkh|ryPM3vwfHNCVkeHUh?=
Mo-TMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfGTWM2OD12Mj64PVU5KM7:TR?=MX\TRW5ITVJ?
CFPAC-1M2\OcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTR|LkS5OFQh|ryPM2TQO3NCVkeHUh?=
CAL-51NYHvcXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTR|LkW2NFUh|ryPMXfTRW5ITVJ?
RH-18MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvoTY55UUN3ME20N{45ODVizszNM1LvbXNCVkeHUh?=
EC-GI-10NXT2ZlVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NECxfWRKSzVyPUSzMlg{PDdizszNNHXOO2RUSU6JRWK=
HSC-2NIKycFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljsTWM2OD12ND6wNFkh|ryPNXfmemM6W0GQR1XS
ML-2M{LiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PMNWlEPTB;NEWuNlYzOSEQvF2=NHHXUG9USU6JRWK=
KNS-81-FDM3vFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfZblZoUUN3ME20OU44OzZ3IN88US=>MWXTRW5ITVJ?
NB6M{DWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\lTWM2OD12Nj6xNVEh|ryPM3jmbXNCVkeHUh?=
MCF7M2KzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHOTWM2OD12Nj61OVM{KM7:TR?=M1nXN3NCVkeHUh?=
P30-OHKMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PtV2lEPTB;NE[uPFEyPyEQvF2=M1jOTHNCVkeHUh?=
BPH-1NWnxNGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDOZ25tUUN3ME20Ok46QDB3IN88US=>MWrTRW5ITVJ?
U251M3zr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrvTWM2OD12Nj65PVQh|ryPMmizV2FPT0WU
MKN1NWn0fXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG3TWM2OD12Nz61NVM4KM7:TR?=NUHtVYRTW0GQR1XS
A431NIfNPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\0TWM2OD12Nz64N|M5KM7:TR?=Ml3kV2FPT0WU
C8166MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILxXodKSzVyPUS5MlIxOzlizszNM{PKbHNCVkeHUh?=
HELMoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTR7LkSwOlQh|ryPMUXTRW5ITVJ?
RMG-IMl34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIqzfYlKSzVyPUS5MlQ1PDRizszNMom4V2FPT0WU
CAL-72NWL3TXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXETWM2OD12OT62NFc2KM7:TR?=NFnjbm9USU6JRWK=
SW962MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTR7LkmzN|Ih|ryPNV\mTXJnW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).

Protocol(Only for Reference)

Kinase Assay:

[1]

Cellular receptor kinase phosphorylation assay Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.

Cell Assay:

[2]

Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
Concentrations 1 nM - 10 μM
Incubation Time 72 hours
Method

Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.

Animal Study:

[3]

Animal Models BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
Formulation 0.5% carboxymethylcellulose (CMC)
Dosages 10, 30 or 100 mg/kg
Administration Oral daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

[2] Rossler, J. et al., Int J Cancer, 2011, 128(11), 2748-2758.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02636725 Not yet recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University  ...more Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2
NCT02639182 Not yet recruiting Metastatic Renal Cell Carcinoma Agensys, Inc.|Astellas Pharma Inc January 2016 Phase 2
NCT02579811 Not yet recruiting Metastatic Renal Cell Cancer Case Comprehensive Cancer Center January 2016 Phase 2
NCT02560012 Not yet recruiting Carcinoma, Renal Cell The University of Texas Health Science Center, Houston December 2015 Phase 2

view more

Chemical Information

Download Axitinib SDF
Molecular Weight (MW) 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AG 013736
Solubility (25°C) * In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Customer Product Validation (4)


Click to enlarge
Rating
Source J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck
Method Spheroid Staining & Sectioning
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time 72 h
Results These results demonstrate that both U0126 and axitinib penetrated into the spheroid, resulting in downregulation of vimentin throughout the whole spheroid by more than 80% as compared to untreated spheroids.

Click to enlarge
Rating
Source J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck
Method Western Blot
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results Based on these data, there appears to be a threshold of 50% downregulation of VimPro-Fluc activity that must be reached before protein downregulation occurs.

Click to enlarge
Rating
Source J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck
Method Secondary assay
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results U0126, pF2341066, axitinib, and pKC412 caused significant inhibition of the invasive potential of Mda-Mb-231 spheroids. Conversely, dasatinib, a potent inhibitor of vimentin gene expression, did not significantly alter the invasive potential of MDA-MB-231 spheroids.

Click to enlarge
Rating
Source Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck
Method Western blot
Cell Lines HUVEC cells
Concentrations 0.1-10 nM
Incubation Time
Results Axitinib treatment blocks VEGFR2 phosphorylation.

Product Use Citation (13)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Axitinib | Axitinib ic50 | Axitinib price | Axitinib cost | Axitinib solubility dmso | Axitinib purchase | Axitinib manufacturer | Axitinib research buy | Axitinib order | Axitinib mouse | Axitinib chemical structure | Axitinib mw | Axitinib molecular weight | Axitinib datasheet | Axitinib supplier | Axitinib in vitro | Axitinib cell line | Axitinib concentration | Axitinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us